Clinical Trial

Single Dose PCSK9 Inhibitor to Improve Cardiovascular Outcomes After PCI: A Pilot Study

Study acronym: HANYANG-PICK
Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This pilot study aims to evaluate whether a single dose of PCSK9 inhibitor administered after percutaneous coronary intervention (PCI) can improve long-term cardiovascular outcomes in patients with high post-PCI lipid core burden, as assessed by NIRS-IVUS. The study will assess major adverse cardiovascular events (MACE) over a 12-month follow-up period.
Trial Details
NCT Number NCT07084259
Lead Sponsor Hanyang University Seoul Hospital
Collaborators: DOTTER Inc.
Conditions Coronary Artery Disease
Enrollment 352 participants
Start Date 2025-07
Primary Completion 2030-06 (estimated)
Study Completion 2030-07 (estimated)
Updated on ClinicalTrials.gov 2025-07-24